ABTI — Alterola Biotech Share Price
0.000.00%
Last trade - 00:00- $7.31m
- $7.55m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -64.97% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.
Directors
- Timothy Rogers CHM (57)
- Seamus McAuley CEO (45)
- Colin Stott COO (54)
- Hunter Land VPR (37)
- Dominic Schiller OTH (57)
- Zohar Koren DRC (47)
- Qu Ning DRC (53)
- Daniel Reshef DRC (69)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 21st, 2008
- Public Since
- March 9th, 2010
- No. of Shareholders
- 140
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,353,646,959
- Address
- 47 Hamilton Squar, BIRKENHEAD, CH415AR
- Web
- https://alterola-abti.com/
- Phone
- +1 9095845853
- Auditors
- Gries & Associates, LLC
Upcoming Events for ABTI
Q1 2025 Alterola Biotech Inc Earnings Release
Similar to ABTI
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Alterola Biotech share price?
As of Today at 19:02 UTC, shares in Alterola Biotech are trading at $0.01. This share price information is delayed by 15 minutes.
How has the Alterola Biotech share price performed this year?
Shares in Alterola Biotech last closed at $0.01 and the price had moved by -88.63% over the past 365 days. In terms of relative price strength the Alterola Biotech share price has underperformed the S&P500 Index by -89.97% over the past year.
What are the analyst and broker recommendations for Alterola Biotech?
There is no consensus recommendation for this security.
What is the Alterola Biotech dividend yield?
Alterola Biotech does not currently pay a dividend.
Does Alterola Biotech pay a dividend?
Alterola Biotech does not currently pay a dividend.
When does Alterola Biotech next pay dividends?
Alterola Biotech does not currently pay a dividend.
How do I buy Alterola Biotech shares?
To buy shares in Alterola Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Alterola Biotech?
As of the previous close price of $0.01, shares in Alterola Biotech had a market capitalisation of $7.31m.
Where are Alterola Biotech shares listed?
Here are the trading details for Alterola Biotech:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ABTI
What kind of share is Alterola Biotech?
Based on an overall assessment of its quality, value and momentum Alterola Biotech is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Alterola Biotech share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Alterola Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alterola Biotech. Over the past six months, its share price has outperformed the S&P500 Index by +16.38%.
As of the last closing price of $0.01, shares in Alterola Biotech were trading -84.44% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Alterola Biotech PE Ratio?
The Alterola Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Alterola Biotech?
Alterola Biotech's management team is headed by:
- Timothy Rogers - CHM
- Seamus McAuley - CEO
- Colin Stott - COO
- Hunter Land - VPR
- Dominic Schiller - OTH
- Zohar Koren - DRC
- Qu Ning - DRC
- Daniel Reshef - DRC